A 35-year-old man from Mumbai returns from a 2-week trip to a malaria-endemic district in Maharashtra. He presents with 3 days of high fever (40.5°C), severe headache, confusion, and one episode of generalised tonic-clonic seizure. On examination, he is drowsy, with neck stiffness and a positive Kernig's sign. Blood pressure is 95/60 mmHg. Thick blood smear shows ring forms with multiple rings per RBC. Serum glucose is 45 mg/dL, lactate is 8 mmol/L, and creatinine is 3.2 mg/dL. What is the most appropriate immediate management?

Explanation

## Severe Malaria with Cerebral Involvement and Metabolic Complications ### Diagnosis: Plasmodium falciparum Cerebral Malaria **High-Yield:** Multiple ring forms per RBC ("appliqué" or "signet ring" appearance) are pathognomonic for P. falciparum. The clinical triad of fever, altered mental status, and seizures in a malaria-endemic setting is cerebral malaria until proven otherwise. ### Why This Is Severe Malaria | Feature | Finding | Significance | |---------|---------|---------------| | **Parasitaemia** | Multiple rings/RBC | P. falciparum (can exceed 10%) | | **CNS involvement** | Confusion, seizure, neck stiffness | Cerebral malaria (WHO severe malaria criterion) | | **Hypoglycaemia** | 45 mg/dL | Severe; increases mortality risk | | **Lactate** | 8 mmol/L (normal <2) | Metabolic acidosis; tissue hypoxia | | **Renal dysfunction** | Creatinine 3.2 mg/dL | Acute kidney injury (WHO criterion for severe malaria) | | **Shock** | BP 95/60 mmHg | Circulatory compromise | **Key Point:** This patient meets WHO criteria for severe malaria: cerebral malaria (impaired consciousness), acute kidney injury, severe anaemia risk, and metabolic acidosis. ### Why Intravenous Artesunate Is Mandatory ```mermaid flowchart TD A[Severe Malaria Suspected]:::outcome --> B{Artesunate Available?}:::decision B -->|Yes| C[IV Artesunate 2.4 mg/kg<br/>at 0, 12, 24 hrs<br/>then daily]:::action B -->|No| D[IV Quinine as bridge]:::action C --> E[Reduce mortality by 35%<br/>vs Quinine]:::outcome D --> F[Switch to Artesunate<br/>when available]:::action C --> G[Manage Hypoglycaemia<br/>Fluid resuscitation<br/>Seizure prophylaxis]:::action G --> H[Supportive ICU care]:::action ``` **Clinical Pearl:** The SEAQUAMAT and AQUAMAT trials (2011) demonstrated that IV artesunate reduces mortality in severe malaria by 35% compared to IV quinine. This is now the WHO-recommended first-line agent for severe malaria globally, including India. **High-Yield:** Artesunate is superior because it: - Rapidly reduces parasitaemia - Prevents sequestration of infected RBCs in microvasculature - Reduces cytokine-mediated inflammation - Has fewer hypoglycaemia episodes than quinine ### Immediate Management Algorithm 1. **IV Artesunate 2.4 mg/kg** at 0, 12, 24 hours, then once daily until patient can tolerate oral medication 2. **Correct hypoglycaemia** — 50 mL of 50% dextrose IV bolus, then continuous glucose monitoring 3. **Fluid resuscitation** — cautious; avoid pulmonary oedema (risk of ARDS). Use crystalloid, target urine output 0.5 mL/kg/hr 4. **Seizure management** — benzodiazepines (lorazepam 2–4 mg IV) for active seizures; consider prophylaxis 5. **Renal support** — monitor creatinine; prepare for dialysis if oliguria worsens 6. **Supportive care** — ICU admission, mechanical ventilation if needed, blood transfusion if Hb <7 g/dL **Warning:** Do NOT perform lumbar puncture in suspected cerebral malaria without CT brain to rule out raised intracranial pressure. CSF is typically normal in cerebral malaria; LP may precipitate herniation. ### Why NOT the Other Options? **Lumbar puncture (Option A):** Contraindicated without neuroimaging; CSF is normal in cerebral malaria. Risk of herniation in raised ICP. **Oral artemether (Option C):** Oral drugs are ineffective in severe malaria; IV route is mandatory. Blood culture is unnecessary and delays treatment. **Chloroquine monotherapy (Option D):** P. falciparum is chloroquine-resistant in India. Monotherapy is inadequate for severe malaria; combination therapy with artesunate is required.